Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Böblingen – page 39

944 clinical trials in Böblingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Böblingen at a glance
944
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

944 trials in Böblingen

Open in trial search

Nephrogenic anaemia

Not yet recruiting

Study on Roxadustat for Treating Anemia in Children with Chronic Kidney Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Darbepoetin Alfa
  • Sponsor:Astellas Pharma Global Development Inc.

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Oncoc4 Inc.

Study Comparing Ivonescimab and Chemotherapy with Pembrolizumab and Chemotherapy for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Summit Therapeutics Inc.

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Dementia Alzheimer's type

Not yet recruiting

Study on BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BIIB080
  • Sponsor:Biogen Idec Research Limited

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Macular oedema

Not yet recruiting

Study on the Effects of RO7200220 for Patients with Uveitic Macular Edema

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vamikibart
  • Sponsor:F. Hoffmann-La Roche AG

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:GPOH gGmbH

Neuroblastoma

Not yet recruiting

Study on Melphalan and Drug Combination for Low and Intermediate Risk Neuroblastoma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:University Of Cologne

Colitis ulcerative

Not recruiting

Evaluation of Long-Term Efficacy and Safety of Obefazimod as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Böblingen

What the registry says about research in the country

01 Neurological Disorders

Groundbreaking research focusing on multiple sclerosis treatments, including studies comparing new therapies like fenebrutinib and frexalimab with established treatments. Several trials are investigating novel approaches for both relapsing and primary progressive forms of MS.

  • Relapsing Multiple Sclerosis
  • Primary Progressive MS
  • Brain Inflammation

Additional studies explore innovative treatments for migraine prevention in patients who haven't responded to conventional therapies.

02 Mental Health Studies

Comprehensive research into major depressive disorder and schizophrenia, evaluating new therapeutic approaches. Trials include testing novel compounds for depression with anhedonia and long-term safety studies for schizophrenia treatments.

  • Depression Treatment
  • Schizophrenia Management
  • ADHD Therapy

Studies also examine new formulations for ADHD treatment in adults, comparing immediate and modified-release medications.

03 Oncology Research

Innovative trials in breast cancer treatment, particularly focusing on HER2-negative and triple-negative variants. Studies evaluate both neoadjuvant and adjuvant therapeutic approaches.

  • Triple-Negative Breast Cancer
  • HER2-Negative Breast Cancer
  • Rectal Cancer

Additional research examines treatment strategies for locally advanced rectal cancer, comparing pre- and post-surgical interventions.

04 Neurodegenerative Conditions

Critical research into Alzheimer's disease and related conditions, with studies focusing on treating associated symptoms like psychosis and agitation in dementia patients.

  • Alzheimer's Psychosis
  • Dementia Management
  • Behavioral Symptoms

These trials aim to improve quality of life for patients with neurodegenerative disorders through targeted symptom management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.